Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Hirsh

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Cancer Research Communications|November 16, 2022
Bcl-xL inhibition radiosensitizes <i>PIK3CA/PTEN</i> wild-type triple negative breast cancers with low Mcl-1 expressionAndrea M Pesch, Benjamin C Chandler, Anna R Michmerhuizen, et al.
Biorxiv : the Preprint Server for Biology|October 3, 2025
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumorsMatthew J Lin, Joanna K Chorazeczewski, Gvantsa Pantsulaia, et al.
JCI Insight|December 21, 2021
RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypesAndrea M Pesch, Nicole H Hirsh, Anna R Michmerhuizen, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Cancer Research Communications|November 16, 2022
Bcl-xL inhibition radiosensitizes <i>PIK3CA/PTEN</i> wild-type triple negative breast cancers with low Mcl-1 expressionAndrea M Pesch, Benjamin C Chandler, Anna R Michmerhuizen, et al.
Biorxiv : the Preprint Server for Biology|October 3, 2025
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumorsMatthew J Lin, Joanna K Chorazeczewski, Gvantsa Pantsulaia, et al.
JCI Insight|December 21, 2021
RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypesAndrea M Pesch, Nicole H Hirsh, Anna R Michmerhuizen, et al.
Pageof 3